ABMRGB.jpg

Home
Our Clinical Staff
Our General Services
Forensic Psychiatry Services
Treatment Resistant Depression Clinic
TRD Clinic Referral Form
Transcranial Magnetic Stimulation (TMS)
KETAMINE
Genetic Testing
ADHD Assessment
Neuropsychiatric EEG-Based Assessment
Insurance Plans
Office Policies
DIRECTIONS
Press & Resources Links
New Patient Paperwork
Prescription Refills

Neuropsychiatric EEG-Based ADHD Assessment 
 
ABM is pleased to now offer Neuropsychiatric EEG-Based Assessment Aid for ADHD (NEBA®), the only FDA approved brainwave-based ADHD assessment aid. 
 
Dr. McCormack stated, “ABM is excited to offer this cutting-edge, brain-based assessment tool to better identify ADHD.  In the recent past doctors have relied upon relatively subjective data in their evaluation of ADHD symptoms. Now with NEBA, a 15 to 20 minute test that integrates an EEG biomarker for ADHD into the traditional ADHD work-up, doctors can utilize more objective data when considering a diagnosis of ADHD.”

Several issues underscore the importance of a thorough, objective evaluation when assessing ADHD symptoms. One concern is that the percentage of US children aged 4 to 17 years old diagnosed with ADHD continues to increase. In addition to the 42% increased rate of ADHD diagnosis between 2003-2011, the percentage of children prescribed ADHD medications between 2007-2011 also increased by 28%.  Furthermore, there are other conditions commonly mistaken for ADHD, such as learning disabilities, hearing or vision problems, anxiety, depression, OCD, or bipolar disorder. Further complicating the issue is the fact that ADHD commonly co-occurs alongside other psychiatric disorders. 

Correctly differentiating between all of these diagnostic possibilities requires more than symptom checklists. Without more objective testing such as NEBA, clinicians might falsely attribute a patient's symptoms to ADHD, rather than another condition. This would not only delay appropriate intervention, but also potentially expose the patient to unnecessary treatments with possible negative side effects. Using NEBA, doctors can significantly reduce the number of patients receiving ADHD treatment as the initial focus when another condition would potentially be the primary diagnosis.  In the FDA validation study, NEBA reduced the potential for over-diagnosis from 34% to 3% and also provided confirmatory support for ADHD with an accuracy of 92%. 

Patients or clinicians interested in obtaining a NEBA evaluation should call (706) 316–1908 for further details.  Because insurance coverage of NEBA varies widely from plan to plan, our office does not file insurance claims for this service. The cost is $325, and we will be happy to provide the patient with the appropriate codes and HCFA-1500 form if they would like to file a claim under their insurance policy themselves. In order to make this valuable test more accessible to a large number of patients, NEBA Health offers a variety of programs, including NEBA-Cares, to provide need-based assistance  for those who qualify. 

webassets/NEBA.jpg
webassets/neba-logo.jpg